Deutsch
English
Русский

Publications 2001 - 2007

Buchwald, B., J. Bufler, M. Carpo, F. Heidenreich, R. Pitz, J. Dudel, E. Nobile-Orazio, K. V. Toyka (2001)
Combined pre- and postsynaptic action of IgG antibodies in Miller Fischer syndrome.
Neurology 56: 67 – 74

Carenini, S., M. Mäurer, A. Werner, H. Blazyca, K. V. Toyka, C. D. Schmid, G. Raivich, R. Martini (2001)
The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in P0
J Cell Biol 152: 301 – 308

Chan, A., T. Magnus, R. Gold, K. V. Toyka (2001)
Phagocytosis of apoptotic inflammatory cells by microgliy and modulation by different cytokines: mechanism for removal of apoptotic cells in the inflamed nervous system
Glia 33: 87 - 95

Hadden, R. D. M., H. Karch, H.-P. Hartung, J. Zielasek, B. Weißbrich, J. Schubert, A. Weishaupt, A. V. Swan, R. A. C. Hughes, K. V. Toyka and the PSGBS trial group (2001)
Preceding infections, immune factors and outcome in Guillain-Barré syndrome
Neurology 56: 758 – 765

Jung, S., S. Gaupp, H.-P. Hartung, K. V. Toyka (2001)
Oral tolerance in experimental autoimmune neuritis (EAN) of the Lewis rat - Adjuvant effects and bystander suppression in P2 peptide-induced EAN
J Neuroimmunol 116: 21-28

Leussink, B., S. Jung, R. Gold, K. V. Toyka (2001)
High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leucocytes
Arch. Neurol. 58: 91 – 97

Moriabadi, N. F., S. Niewiesk, N. Kruse, S. Jung, B. Weissbrich, V. ter Meulen, K. V. Toyka, P. Rieckmann (2001)
Influenza vaccination in MS - Absence of T-cell response against white matter proteins
Neurology 56: 938 - 943

Weishaupt, A., L. M. Schönrock, M. Stienekemeier, K. V. Toyka (2001)
Glucocorticosteroids modulate antigen-induced T-cell apoptosis in experimental autoimmune neuritis and cause T-cell proliferation in situ
Acta Neuropathol 102: 75 - 82

Wessig, C., B. Buchwald, K. V. Toyka, R. Martini (2001)
Miller Fisher Syndrome: immunofluorescence and immunoelectron microscopic localization of IgG at the mouse neuromuscular junction
Acta Neuropathol 101: 239-244

Mäurer, M., C. D. Schmid, F. Bootz, J. Zielasek, K. V. Toyka, S. Oehen, R. Martini (2001)
Bone marrow transfer from wild-type mice reverts the beneficial effect of genetically mediated immune deficiency in myelin mutants
Mol. Cell. Neurosci 17: 1094 – 1101

Korn, T., K. V. Toyka, H.-P. Hartung, S. Jung (2001)
Suppression of experimental autoimmune neuritis by leflunomide
Brain 124: 1791 - 1802

Weishaupt, A., W. Brück, T. Hartung, K. V. Toyka, R. Gold (2001)
Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor- alpha 945;
J. Neuroimmunol. 306: 77 - 80

Flachenecker, P., K. Reiners, M. Krauser, A. Wolf, K. V. Toyka (2001)
Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability
Mult. Sclerosis 7: 327 – 334

Stienekemeier, M., K. Falk, O. Rotzschke, A. Weishaupt, C. Schneider, K. V. Toyka, R. Gold, J.L. Strominger (2001)
Vaccination , prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope.
Proc. Nat. Acad. Sci. (USA) 98: 13872 –13877

Sommer, C., T. Lindenlaub, P. Teuteberg, M. Schäfers, T. Hartung, K. V. Toyka (2001)
Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy
Brain Res. 913: 86 – 89

Magnus, T., A. Chan, O. Grauer, K. V. Toyka, R. Gold (2001)
Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation
J. Immunol. 167: 5004 – 5010

Schneider, C., R. Gold, K. Reiners, K. V. Toyka (2001)
Mycophenolate mofetil in the therapy of severe myasthenia gravis.
Eur. Neurol. 46: 79 - 82

Buchwald, B., R. Ahangari, A. Weishaupt, K. V. Toyka (2002)
Intravenous immunoglobulins neutralize blocking antibodies in the Guillain-Barré syndrome.
Ann. Neurol. 51: 673 – 680

Giess, R., B. Holtmann, M. Braga, T. Grimm, B. Müller-Myhsok, K. V. Toyka, M. Sendtner (2002)
Early onset of severe familial ALS with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene.
Am J of Human Genetics 70: 1277 – 1286

Magnus, T., M. Beck, R. Giess, I. Puls, M. Naumann, K. V. Toyka (2002)
Disease progression in amyotrophic lateral sclerosis: predictors of survival
Muscle Nerve 25: 709 - 714

Giess, R., M. Mäurer, R. Linker, R. Gold, M. Warmuth-Metz, K. V. Toyka, M. Sendtner, P. Rieckmann (2002)
Association of a null mutation in the CNTF gene with early onset of multiple sclerosis.
Arch. Neurol. 59: 407 – 409

Giess, R., E. Werner, M. Beck, C. Reiners, K. V. Toyka, M. Naumann (2002)
Impaired salivary gland function reveals autonomic dysfunction in ALS
J. Neurol. 249: 1246 - 1249

Beck, M., K. V. Toyka (2002)
Progressive sudomotor dysfunction in amyotrophic lateral sclerosis
J. Neurol. Neurosurg. 73: 68 - 70

Linker, R. A., S. Gaupp, M. Mäurer, R. Martini, B. Holtmann, R. Giess, P. Rieckmann, K. V. Toyka H. Lassmann, M. Sendtner, R. Gold (2002)
CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation
Nature Med. 8: 620 - 624

Magnus T, A, Chan, R.A. Linker, K.V. Toyka, R. Gold (2002)
Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: implications for the role of glial cells in the inflamed central nervous system
J Neuropath. Exp. Neurol. 61: 760 - 766

Flachenecker, P., T. Kumpel, B. Kallmann, M. Gottschalk, O. Grauer, P. Rieckmann, C. Trenkwalder, K. V. Toyka (2002)
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters
Mult. Scler. 8: 523 - 526

Weishaupt, A., T. Kuhlmann, L.M. Schönrock, K.V. Toyka, W. Brück, R. Gold (2002)
Effects of intravenous immunoglobulins on T cell and ologodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis.
Acta Neuropathol. 104: 385 – 390

Müllges, W., J. Babin-Ebell, W. Reents, K.V. Toyka (2002)
Cognitive performance after coronary artery bypass grafting: a follow-up study.
Neurology 59: 741 – 743

Beer, M., Schneider, C., H. Kostler, S. Buchner, J. Sandstede, K.V. Toyka, D. Hahn (2002)
Quantitative analysis of energy metbolism in human muscle using SLOOP 31P -MR-spctroscopy.
Röfo Fortschr. Röntgenstr. Neuen Bildgeb. Verfahr. 174: 573 - 578

Weiss, H., V. Rastan, W. Müllges, R. F. Wgner, K. V. Toyka (2002)
Psychotic symptoms and emotional distress in patients with Guillain-Barre syndrome.
Eur Neurol. 47: 74 – 78

Bayas, A., V. Hummel, B. Kallmann, K.V. Toyka, P. Rieckmann (2002)
Human cerebral endothelial cells are a potential source for bioactive BDNF.
ytokine 19 : 55 – 58

Krampfl, K., B. Mohammadi, B. Buchwald, K. Jahn, R. Dengler, K.V. Toyka, J. Bufler (2003)
IgG from patients with Guillain-Barre syndrome interact with nicotinic acetylcholine receptor channels.
Muscle Nerve 27 : 435 - 441

Buchwald, B., R. Ahangari, K.V. Toyka (2003)
Differential blocking effects of a monoclonal anti-GQ1b IgM antibody and of alpha-latrotoxin.
Neurosci. Lett. 334 : 25 - 28

Kahl, KG, J. Zielasek, L.O. Uttenthal, J. Rodrigo, K.V. Toyka, H.H.Schmidt (2003)
Protective role of cytokine-inducible isoform of nitric oxide synthase induction and nitrosative stress in experimental autoimmune encephalomyelitis of the DA rat.
J. Neurosci Res. 15 : 198 – 205

Schmidt, J., J.M. Metselaar, M.H. Wauben, K.V. Toyka, G. Storm, R. Gold (2003)
Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis.
Brain 126 : 1895 –1904

Müllges, W, D. Franke, W. Reemts, J. Babin-Ebell, K.V. Toyka (2003)
Reduced rate of microembolism by optimized aortic canula position does not influence early postoperative cognitive performance in CABG patients.
Cerebrovasc. Dis. 15 : 192 – 198

I. Kobsar, M. Berghoff, M. Samsam, C. Wessig, M. Mäurer, K.V. Toyka, R. Martini (2003)
Preserved myelin integrity and reduced axonopathy in connexin 32-deficient mice lacking the recombinant activating gene-
Brain 126 : 804 – 813

Schneider-Gold, C., M. Beck, C. Wessig, A. George, H. Kele, K. Reiners, K.V. Toyka (2003)
Creatine monohydrate in proximal myotonic myopathy (DM2/PROMM) : a double blind placebo-controlled study.
Neurology 60 : 500 – 5002

Jann, S., M.A. Bramerio, S. Beretta, S. Koch, C.A. Defanti, K.V. Toyka, C. Sommer (2003)
Diagnostic value of sural nerve matric metalloproteinase-9 in diabetic patients with CIDP :
Neurology 61 : 1607 – 1610

Kleinschnitz C., M. Bendszus, M. Frank, L. Solymosi, K.V. Toyka, G. Stoll (2003)
In vivo monitoring of macrophage infiltration in experimental ischemic brain lesions by magnetic resonance imaging.
J. Cereb. Blood Flow Metabol. 23 : 1356 – 1361

Flachenenecker P., A. Rufer, I. Bihler, C. Hippel, K. Reiners, K.V. Toyka, J. Kesselring (2003)
Fatigue in MS is related to sympathetic vasomotor dysfunction. Neurology 61 : 851 – 853

Wessig, C., R. Klein, M.F. Schneider, K.V. Toyka, M. Naumann, C. Sommer (2003)
Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome.
Neurology 61 : 195 – 198

Flachenecker P., C. Schneider, S. Cursiefen, K. Ricker, K.V. Toyka, K. Reiners (2003)
Assessment of cardiovascular autonomic function in myotonic dystrophy type 2 (DM2/PROMM)
Neuromucul. Disord. 13 : 289 – 293

Mäurer, M. G. Stoll, K.V. Toyka (2004)
Multifocal motor neuropathy presenting as chronic progressive proximal leg weakness.
Neuromuscul. Disord. 14: 380 - 382

Flachenecker, P., I. Bihler, F. Weber, M. Gottschalk, K.V. Toyka, P. Rieckmann (2004)
Cytokine mRNA expression in patients with multiple sclerosis and fatigue.
Mult Sclerosis 10: 165 - 169

Stoll, G, C. Wesemeier, R. Gold, L. Solymosi, K.V. Toyka, M. Bendszus (2004)
In vivo monitoring of macrophage infiltration in experimental autoimmune neuritis by magnetic resonance imaging.
J Neuroimmunol. 149: 142 - 146

Kahl, K.G., H.H. Schmidt, S. Jung, P. Sherman, K.V. Toyka, J. Zielasek (2004)
Experimental autoimmune encephalomyelitis in mice with a targeted deletion of the inducible nitric oxide synthase gene: increased T-helper 1 response.
Neurosci Lett. 358: 58-62

Jung, S, S. Gaupp, T. Korn, G. Kollner, H.-P. Hartung, K.V. Toyka (2004)
Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization.
J Neurosci Res. 75: 524 - 535

Schneider-Gold, C., M. Beer, H. Kostler, S. Buchner, J. Sandstede, D. Hahn, K.V. Toyka (2004)
Cardiac and skeletal muscle involvement in myotonic dystrophy type 2 (DM2): A quantitative (31)P-MRS and MRI study.
Muscle Nerve 27: 636 - 644

Strobel P, A. Bauer, B. Puppe, T. Kraushaar, A. Krein, K.V. Toyka, R. Gold, M. Semik, R. Kiefer, W. Nix, B. Schalke, H. K. Muller-Hermelink, A. Marx (2004).
Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis.
J Clin Oncol. 22:1501 - 1509

Rieckmann P, K.V. Toyka and the Multiple Sclerosis Therapy Consensus Group (2004)
Escalating immunotherapy of multiple sclerosis--new aspects and practical application.
J Neurol. 251:1329-1339

Bendszus M, M. Koltzenburg, A.J. Bartsch, R. Goldbrunner, T. Günthner-Lengsfeld, F.X. Weilbach, K. Roosen, K.V. Toyka, L. Solymosi (2004)
Heparin and air filters reduce embolic events caused by intra-arterial cerebral angiography: a prospective, randomized trial.
Circulation. 12;110:2210-2215

Korn T, T. Magnus, K.V. Toyka, S. Jung (2004)
Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
J Leukoc Biol. 76:950-960

Sommer, C, A. Weishaupt, J. Brinkhoff, L. Biko, C. Wessig, R. Gold, K.V. Toyka (2004).
Paraneoplastic stiff-person syndrome: Passive transfer to the rat with IgG antibodies to amphiphysin.
Lancet (in press)

Schoser, B.G., C. Schneider-Gold, W. Kress, H.H. Goebel, P. Reilich, M.C. Koch, D.E. Pongratz, K.V. Toyka, H. Lochmuller, K. Ricker (2004)
Muscle pathology in 57 patients with myotonic dystrophy type 2.
Muscle Nerve. 29: 275 - 281.

Jung, S, S. Gaupp, T. Korn, G. Kollner, H.-P. Hartung, K.V. Toyka (2004)
Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization.
J Neurosci Res. 75: 524 - 535.

Schneider-Gold, C., M. Beer, H. Kostler, S. Buchner, J. Sandstede, D. Hahn, K.V. Toyka (2004)
Cardiac and skeletal muscle involvement in myotonic dystrophy type 2 (DM2): A quantitative (31)P-MRS and MRI study.
Muscle Nerve 30: 636 - 644

Bendszus M, M. Koltzenburg, A.J. Bartsch, R. Goldbrunner, T. Günthner-Lengsfeld, F.-X. Weilbach, K. Roosen, K.V. Toyka, L. Solymosi (2004)
Heparin and air filters reduce embolic events caused by intraarterial cerebral angiography: a prospective, randomized trial. Circulation 110:2210 – 2215

Berghoff M, M. Samsam, M. Müller, I. Kobsar, K.V. Toyka, R. Kiefer, M. Mäurer, R. Martini. (2005)
Neuroprotective effect of the immune system in a mouse model of severe dysmyelinating hereditary neuropathy: enhanced axonal degeneration following disruption of the RAG-1 gene.
Mol Cell Neurosci. 28:118-127

Chan A, F.X. Weilbach, K.V. Toyka, R. Gold (2005)
Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.
Clin Exp Immunol. 139:152-158

Buchwald B, R. Ahangari, A. Weishaupt, K.V. Toyka (2005)
Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: Their neutralization by intravenous immunoglobulins.
Muscle Nerve. 31

Buchwald B, R. Ahangari, A. Weishaupt, K.V. Toyka (2005)
Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins.
Muscle Nerve. 31:487 - 494.

Bates D, K. V. Toyka, J. S. Wolinsky, D. Arnold (2005)
Disease management in multiple sclerosis.
Eur Neurol. 53:203-205.

Hofstetter HH, Mossner R, Lesch KP, Linker RA, Toyka KV, Gold R. (2005)
Absence of reuptake of serotonin influences susceptibility to clinical autoimmune disease and neuroantigen-specific interferon-gamma production in mouse EAE.
Clin Exp Immunol. 142:39-44.

Schneider-Gold C, P. Gajdos, K.V. Toyka, R. Hohlfeld (2005)
Corticosteroids for myasthenia gravis.
Cochrane Database Syst Rev. CD002828.

Gold, R., G. Stoll, H.-P. Hartung, B. Kieseier, K.V. Toyka (2005)
Experimental autoimmune neuritis. In: Peripheral Neuropathy, 4th edition, P.J. Dyck et al, (eds), Elsevier pp. 609 – 634

Hartung, H.-P., B. Kieseier, R. Gold, Stoll, G., Toyka, K.V. (2005)
Introduction to immune reactions in the peripheral nervous system. In: Peripheral Neuropathy,
4th edition, P.J. Dyck et al, (eds), Elsevier, pp. 559 – 572

Reinhardt M, P. Hauff, R. A. Linker, A. Briel, R. Gold, P. Rieckmann, G. Becker, K. V. Toyka, M. Maurer, M. Schirner (2005)
Ultrasound derived imaging and quantification of cell adhesion molecules in experimental autoimmune encephalomyelitis (EAE) by Sensitive Particle Acoustic Quantification (SPAQ).
Neuroimage 27:267-278

Sommer C, Koch S, Lammens M, Gabreels-Festen A, Stoll G, Toyka KV (2005)
Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP.
Neurology 65:1924-1929

Sommer, C, A. Weishaupt, J. Brinkhoff, L. Biko, C. Wessig, R. Gold, K.V. Toyka (2005).
Paraneoplastic stiff-person syndrome: Passive transfer to the rat with IgG antibodies to amphiphysin. Lancet 365: 1406 - 1411

Stasiolek M, Bayas A, Kruse N, Wieczarkowiecz A, Toyka KV, Gold R, Selmaj K. (2006)
Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain. 129:1293-1305

Toyka KV (2006) Ptosis in myasthenia gravis: extended fatigue and recovery bedside test.
Neurology 67:1524

Gajdos P, Chevret S, Toyka KV. (2006)Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2006 Apr 19;(2)

Beck M, M. Sendtner, K. V. Toyka (2007)
Novel SOD1 N86K mutation is associated with a severe phenotype in familial ALS.
Muscle Nerve 36:111-114.

Henze T, Rieckmann P, Toyka KV; Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society (2006) Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 56(2):78-105

Hofstetter HH, Toyka KV, Tary-Lehmann M, Lehmann PV (2007).
Kinetics and Organ Distribution of IL-17-Producing CD4 Cells in Proteolipid Protein 139-151 Peptide-Induced Experimental Autoimmune Encephalomyelitis of SJL Mice.
J Immunol. 178:1372-1378.

Siglienti I, Chan A, Kleinschnitz C, Jander S, Toyka KV, Gold R, Stoll G (2007)
Downregulation of transforming growth factor-beta2 facilitates inflammation in the central nervous system by reciprocal astrocyte/microglia interactions.
J Neuropathol Exp Neurol. 66:47-56.

Uceyler N, J. P. Rogausch, K. V. Toyka, C. Sommer (2007)
Differential expression of cytokines in painful and painless neuropathies.
Neurology 69:42-49

Auswahl sonstiger Publikationen

Hartung, H.-P, K. V. Toyka (1998)
Immunpathologie und Immuntherapie
In: K. Kunze (ed.), Lehrbuch der Neurologie, 2. Aufl., Thieme, Stuttgart p. 89 - 123

Hartung, H.-P., K. V. Toyka, J. W. Griffin (1998)
Guillain-Barré Syndrome and chronic inflammatory demyelinating Polyradiculoneuropathy in: Clinical Neuroimmunology, J. Antel, G. Birnbaum, H.-P. Hartung
Blackwell Science, Oxford, p. 294 - 306

Hohlfeld, R., K. V. Toyka (1998)
Myasthenia gravis - Myasthenie-Syndrome
In: K. Kunze (ed.), Lehrbuch der Neurologie, 2. Aufl., Thieme, Stuttgart p. 169 - 178

Martini, R., J. Zielasek, K. V. Toyka (1998)
Inherited demyelinating neuropathies: from gene to disease
Curr. Opin. Neurol. 11: 545 - 556

Naumann, M., W. H. Jost, K. V. Toyka (1999)
Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system
Arch. Neurol. 56: 914 - 916

Rieckmann, P., K. V. Toyka et al (1999)
Escalating immunotherapy of multiple sclerosis
Eur. Neurol. 42: 121 - 127

Stangl, M., K. V. Toyka, R. Gold (1999)
Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases
Arch. Neurol., 56: 661 - 663

Toyka, K. V. (1999)
Eighty three years of the Guillain-Barré Syndrome: clinical and immunopathologic aspects, current and future treatments
Rev. Neurol.155: 10, 849 - 856

K. V. Toyka, R. Hohlfeld (1999)
Myasthene Syndrome
Danuschke et al (Hrsg.)
in: Therapie-Handbuch Urban & Schwarzenberg, p 15

Zielasek, J., K. V. Toyka (1999)
Nerve conduction abnormalities and neuromyotonia in genetically engineered mouse models of human hereditary neuropathies
Ann. N. Y. Acad. Sci. 883: 310 - 320

Gold, R., H.-P. Hartung, K. V. Toyka (2000)
Animal models for autoimmune demyelinating disorders of the nervous system
Mol. Med. Today 6: 88 - 91

Gold, R. F. Buttgereit, K. V. Toyka (2001)
Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders
J. Neuroimmunol. 117: 1 - 8

Willison, H., G. Stoll, K. V. Toyka, T. Berger, H.-P. Hartung (2002)
Autoimmunity and inflammation in the peripheral nervous system.
Trends Neurosci. 25: 127 – 9

Gold, R., M. Dalakas, K.V. Toyka (2003)
Immunotherapy in autoimmune neuromuscular disorders.
Lancet Neurol 2: 22 –32

Toyka, K.V., R. Gold (2003)
The pathogenesis of CIDP: rationale for immunomodulatory treatment.
Neurology 60: S 2 – 7

Wolinsky, J.B., K.V. Toyka, L. Kappos, S. Grossberg (2003)
Interferon-ß antibodies: implications for the treatment of MS.
Lancet Neurol. 2 : 528

Hohlfeld, R., A. Melms; C. Schneider, K.V. Toyka, D.B. Drachman (2003)
Therapy of Myasthenia gravis and Myasthenic Syndrome.
In: Dichgans J. et al, (Eds) Neurological Disorders: Course and Treatment, 2nd Ed.
Elsevier, New-York- Amsterdam

Martini R, K. V. Toyka (2004)
Immune-mediated components of hereditary demyelinating neuropathies: lessons from animal models and patients.
Lancet Neurol. 3:457-465

Gold, R., G. Stoll, H.-P. Hartung, B. Kieseier, K.V. Toyka (2005)
Experimental autoimmune neuritis.
In: Peripheral Neuropathy, 4th edition, P.J. Dyck et al, (eds), Elsevier pp. 609 – 634

Hartung, H.-P., B. Kieseier, R. Gold, Stoll, G., Toyka, K.V. (2005)
Introduction to immune reactions in the peripheral nervous system.
In: Peripheral Neuropathy, 4th edition, P.J. Dyck et al, (eds), Elsevier pp. 559 – 572